Iveric Bio Acquired by Japanese Healthcare Company Astellas Pharma for $5.9 Billion

Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of approximately $5.9 billion.
Iveric Bio focuses on discovering and developing novel treatments in the field of ophthalmology. Astellas expects the deal to advance its primary focus on “Blindness & Regeneration.”
The company announced in February 2023 that the FDA accepted a marketing application seeking approval for Avacincaptad Pegol (ACP) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Read the source article at finance.yahoo.com